SBI Securities Co. Ltd. Buys Shares of 5,170 Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

SBI Securities Co. Ltd. bought a new position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) during the 4th quarter, HoldingsChannel.com reports. The fund bought 5,170 shares of the company’s stock, valued at approximately $50,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Atria Investments Inc acquired a new position in Global X Genomics & Biotechnology ETF in the third quarter worth approximately $122,000. Centaurus Financial Inc. increased its stake in shares of Global X Genomics & Biotechnology ETF by 7.0% during the 3rd quarter. Centaurus Financial Inc. now owns 14,996 shares of the company’s stock worth $169,000 after purchasing an additional 985 shares during the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of Global X Genomics & Biotechnology ETF during the 3rd quarter valued at $205,000. Flow Traders U.S. LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the 3rd quarter valued at $936,000. Finally, Oxinas Partners Wealth Management LLC bought a new stake in Global X Genomics & Biotechnology ETF in the fourth quarter worth $103,000. 56.95% of the stock is owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Price Performance

Global X Genomics & Biotechnology ETF stock opened at $8.77 on Tuesday. Global X Genomics & Biotechnology ETF has a one year low of $8.64 and a one year high of $12.10. The company’s fifty day moving average price is $9.77 and its two-hundred day moving average price is $10.38. The company has a market capitalization of $61.13 million, a price-to-earnings ratio of -3.75 and a beta of 1.03.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.